FAQ on Aditxt Inc.'s May 2 Update Featuring Mayo Clinic's Dr. Charles Howe on ADI-100™ Preclinical Study

What is the main topic of the May 2 update by Aditxt Inc.?

The main topic is the discussion of key findings from a preclinical study of ADI-100™, Aditxt’s lead therapeutic candidate, by Dr. Charles Howe of the Mayo Clinic, along with updates on immune modulation therapy advancements.

Who will be featured in the Aditxt Inc. update on May 2, 2025?

The update will feature Dr. Charles Howe from the Mayo Clinic, Dr. Shahrokh Shabahang, Aditxt’s Chief Innovation Officer, and Dr. Friedrich Kapp, Co-CEO of Adimune.

Why is the ADI-100™ preclinical study significant?

The study is significant as it represents advancements in immune modulation therapy, potentially leading to innovative health solutions for urgent health challenges.

How can I view the full press release about this update?

The full press release can be viewed at https://ibn.fm/3imFv.

What is Aditxt Inc.’s mission?

Aditxt’s mission is to accelerate promising health innovations through its ecosystem of research institutions, industry partners, and shareholders, focusing on immune health, precision health, public health, and women’s health.

What are Aditxt Inc.’s current programs?

Aditxt currently operates programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

Where can I find the latest news and updates relating to ADTX?

The latest news and updates are available in the company’s newsroom at https://ibn.fm/ADTX.

What is the significance of Aditxt’s arrangement with Appili Therapeutics Inc. and Evofem?

These arrangements aim to expand Aditxt’s programs into public health and women’s health, subject to certain conditions, including shareholder approval and sufficient capital raising.